Ukraine: Only Trump Can Bring Peace; Epstein Revelations Threaten…

Breaking News from Newsmax.com

• Ukraine Says Only Trump Can Broker Deal

Special: What Your Heartburn Is Really Trying to Tell You

• Pressure Grows on Britain’s Starmer Over Epstein Revelations

• Japan’s Takaichi Wins Sweeping Mandate in Parliamentary Election

Is Your Heartburn Trying to
Tell You Something?

It could be a warning sign
of something far more dangerous.

Most people shrug off occasional heartburn — thinking it’s just something they ate. But that burning in your chest may actually be your body’s cry for help.

➤ More than 60 million Americanssuffer from heartburn each month. For many, it’s more than an inconvenience — it’s the beginning of something far worse.

New research shows that chronic heartburn can be a red flag for esophageal, stomach, colorectal, and even lesser-known gastrointestinal cancers — some of the most aggressive and deadly cancers out there.

That’s why we’ve created the FREE Heartburn Prevention Kit — a vital resource that could protect you or someone you love.

---

Here’s what you’ll get — absolutely FREE:

• How to uncover the real root causes of your heartburn
• Simple steps to reduce symptoms without harmful drugs
• Signs that your heartburn may be the early stage of GI cancer
• What your doctor might not tell you about PPIs and antacids
• The shocking connection between low stomach acid and reflux

Warning: A deadly form of gastrointestinal cancer is on the rise — estimated to take over 52,000 lives this year alone. In many cases, it starts with mild, persistent heartburn.

You’ll Also Learn:

• Why many heartburn drugs can actually worsen your condition
• The most effective natural ways to neutralize acid and inflammation
• What your symptoms say about the overall health of your digestive system

This is your chance to get ahead of serious illness before it’s too late.

Click Here to Claim Your FREE Kit!

To a heartburn-free life,
Your Friends at Health Radar

This email is never sent unsolicited. You have received this Newsmax email because you subscribed to it or someone forwarded it to you. To opt out, see the links below.

Remove your email address from our list or modifyyour profile. We respect your right to privacy. Viewour policy.

This email was sent by:
Newsmax.com
362 N. Haverhill Road
West Palm Beach, FL 33415 USA

DM917485
010102qs7741

What is the minimum legal age to drink alcohol…

Play against others for extra points!Try Battle mode▶

Quiz of the day!

 60 PTSGENERALWhat is the minimum legal age to drink alcohol in the United States?

 16

 18

 21

 25Play Classic mode

Would you like to share this with a friend?Invite a Friend

 

One of your friends sent you this?Sign up herePreferencesUnsubscribe

© 2026, Quiz Treat. All rights reserved.

They missed 2025 playoffs. Is ’26 WS in reach?

Sunday, February 08

View In Browser 

TOP NEWS 

Drafting potential rebound World Series matchups

Tonight’s Super Bowl teams both missed the postseason last season, leaving us to ponder World Series matchups we could see this year between 2025 non-playoff clubs. 

Mexico Red tops Mexico Green in thrilling Caribbean Series final

The top projected players to change teams this offseason

Terrance Gore, speedster who made mark with Royals, passes away at 34

These are the storylines that will dominate Cubs camp 

New year, new questions facing Blue Jays

These Cards prospects could be on the fast track to St. Louis 

MORE TOP NEWS

PERSONALIZE STORIES 

 

PLAY A SPORCLE BASEBALL QUIZ! 

MORE FREE GAMES AT MLB PLAY 

STAFF PICKS 

The top projected players to change teams this offseason

With Spring Training camps opening in the coming days, this is a good time to take stock of the most impactful players who will be wearing a different uniform to start 2026. 

Sax honors son through digital baseball art

After five-time All-Star Steve Sax lost his son, John, in a military aircraft accident in 2022, he turned it into an opportunity to raise money to help young people follow in John’s footsteps.

 

New Marlins jerseys a blast from the past

Bringing back memories of the early days of the franchise, the Marlins will wear throwback uniforms featuring teal jerseys during Sunday home games this season.

 

From down on the farm to the Super Bowl

Russell Wilson is among those who have played on both the NFL’s grandest stage and in the lowest rungs of the Minor Leagues.

 

NFCA Division I Leadoff Classic doubleheader

Catch some Division I softball action with Southeastern Louisiana vs. Oregon at 10 a.m. ET, followed by Missouri against South Alabama at 1 p.m. ET on MLB Network.

MORE STORIES 

 

© 2026 MLB Advanced Media, L.P. MLB trademarks and copyrights are used with permission of Major League Baseball. Visit MLB.com. Any other marks used herein are trademarks of their respective owners.

Please review our Privacy Policy.

You (pahovis@aol.com) received this message because you registered to receive commercial email messages from MLB.com.

Please add info@marketing.mlbemail.com to your address book to ensure our messages reach your inbox. If you no longer wish to receive commercial email messages from MLB.com, please unsubscribe  or log in and manage your email subscriptions.

Postal Address: MLB.com, c/o MLB Advanced Media, L.P., 1271 Avenue of the Americas, New York, NY 10020.

7 Reasons Life Insurance Should Be in Your Estate…

Retirement ReportsRetirement ArticlesBrought to you by Eagle Financial Publications7 Reasons Life Insurance Should Be in Your Estate Planby Bob Carlson Editor, Retirement Watch02/08/2026SPONSOREDFlorida Is Testing New Alternative PesticideMed-X is moving toward a possible Nasdaq listing (ticker: MXRX) — and once that happens, the early window closes.  Before Wall Street prices it in, Med-X has already generated $6.4M in sales, placed Nature-Cide on Amazon.com, Walmart.com, and Kroger.com, and begun expanding into 41+ global markets. Florida’s mosquito control districts—America’s most well-funded and influential—are independently testing Nature-Cide botanical pesticides, as Med-X pursues WHO pre-qualification for global public health adoption.  This is the gap before the bell. Review the Med-X opportunity now — before Nasdaq plans unfold. Disclosures: This is a paid advertisement for Med-X’s Regulation A+ Offering. Please read the offering circular at invest.medx-rx.comCLICK HERE…Fellow Investor, Life insurance used to be an essential element of most estate plans, but it hasn’t been for about 20 years.  Important changes, however, make it time for many people to give serious thought to including life insurance in their estate plans.  In this article, I’m talking about permanent life insurance, not termlife insurance.  There’s a place for term insurance in financial plans, but today we’re going to look at how permanent life insurance improves estate plans and retirement plans – including the 7 ways listed below.  First off, keep in mind that the substantial increases in the lifetime estate and gift tax exemption (in the 2001 tax law and again in the 2017 law) meant fewer and fewer people had to worry about how their federal estate taxes would be paid.  That made permanent life insurance less important.  But there’s a real possibility the estate tax exemption (currently $12.92 million per individual) will be reduced in the coming years, either by an act of Congress or when the 2017 tax law expires after 2025.  More importantly, inherited traditional IRAs and 401(k)s always have been heavily taxed assets, and those taxes are increasing.  That trend began with the Setting Every Community Up for Retirement Enhancement (SECURE) Act in 2019, which effectively eliminated an estate planning strategy nicknamed the “Stretch IRA.”  More taxes and restrictions on traditional retirement accounts are in the queue in Congress with bipartisan support.  Life insurance can help reduce those taxes and increase the after-tax wealth of you and your heirs.  Here are 7 reasons to consider including life insurance in your estate plan, especially as a strategy to reposition traditional IRAs and 401(k)s.  1. Life insurance benefits are tax-free to beneficiaries They are one of the few tax-free assets and forms of income in the tax code and one of the longest-established tax-free assets.  By contrast, after traditional IRAs and 401(k)s are inherited, the beneficiaries pay taxes at their ordinary income tax rates on the distributions they take.  2. The beneficiaries only inherit the after-tax value of retirement accounts The SECURE Act potentially increases taxes on inherited IRAs by requiring the accounts to be distributed within 10 years.  The beneficiary pays taxes faster than in the past, and because the distributions can’t be spread over a longer period, it’s more likely the income will be bunched into a few years and push the beneficiary into a higher tax bracket.  3. The longer you keep wealth in a traditional IRA, the more likely it is to appreciate  The appreciation increases future income taxes.  Also, required minimum distributions (RMDs) must be taken from a traditional IRA by the owner after age 72.  You have less control over your future income taxes and the amount your beneficiaries will inherit because of the RMDs.  Of course, income tax rates seem likely to rise in the future because of the federal budget situation and the push in Congress for higher spending.  4. The longer money stays in a traditional IRA, the higher the future taxes on distributions are likely to be With permanent life insurance, the minimum amount your beneficiaries will receive is guaranteed.  It isn’t subject to market fluctuations the way IRA investments are.  In addition, life insurance benefits might increase over time, depending on the type of policy you select. Is China About To Send Relief Money To America?That may seem insane…but something similar has happened before.  And with the US speeding towards a deadly market pit that could send millions into poverty…  It may be about to happen again.  Click here for the strange truth.CLICK HERE…5. Permanent life insurance also can provide tax-free cash during your retirement years In most policies, some cash can be taken as tax-free distributions from the cost basis of the policy, and additional cash can be taken as loans of the policy benefits.  The loans are both tax-free and penalty-free. They don’t need to be paid back, though outstanding loans will reduce the benefit paid to heirs.  Insurance policy cash distributions and loans also won’t trigger the Stealth Taxes, such as taxes on Social Security benefits and the Medicare premium surtax.  The life insurance benefits also can avoid the federal estate tax without using part of your lifetime estate and gift tax exemption.  To do this, you can’t own the insurance policy.  It must be owned by an irrevocable trust or other independent entity, and that could limit your ability to take lifetime cash distributions or loans.  6. Repositioning a traditional IRA or 401(k) as permanent life insurance also creates leverage for your retirement plan A dollar deposited in the insurance policy results in more than one dollar in life insurance benefits.  The extent of the leverage depends on your age and the type of policy you choose. But in most cases, the life insurance benefits are going to equal or exceed the pre-tax value of the traditional IRA balance and exceed its after-tax value.  Often, it would take years of steady investment returns for the after-tax value of a traditional IRA to exceed the life insurance benefits.  Plus, the life insurance benefits would be guaranteed and tax free, two qualities the traditional IRA won’t have, and could have the potential to increase.  Permanent life insurance traditionally was used in estate plans to pay estate taxes or debts, and still can be used that way.  They also can be used to ensure an inheritance so the rest of your assets can be spent during retirement and will be available to pay for any long-term care needs.  But today, converting all or part of a traditional IRA to permanent life insurance should be explored if you have a substantial IRA, plus other income and assets to fund retirement.  7. All of the IRA isn’t needed to ensure retirement securityOften in these situations, the IRA primarily is intended to be inherited by heirs and secondarily is a source of emergency cash for the owner.  Of course, other assets also can be converted to permanent life insurance and will generate benefits.  But traditional IRAs and 401(k)s are especially ripe for being re-positioned as life insurance, because there’s a heavy tax burden on the IRAs and that burden is likely to increase over the years.  Because the SECURE Act also applies to Roth IRAs, it might be beneficial to reposition a Roth IRA as life insurance.  One strategy is to take annual distributions from a traditional IRA, either as RMDs or before RMDs begin. Some people take more than the RMDs.  Use the after-tax distributions to pay annual premiums on a permanent life insurance policy.  Another strategy is to take a larger distribution from the IRA. Some people take a distribution of the entire traditional IRA, though this could push them into the highest income tax bracket for the year.  Others take the maximum lump sum they can without pushing them into the next higher income tax bracket.  Then, the after-tax value of the distribution is used to make a lump-sum deposit on a permanent life insurance policy.  This can be done one time or each year for a period of years.  Congress changed the rules on IRAs several times and more changes are planned.  Many IRA owners need to change their strategies to reduce or eliminate those taxes, creating higher after-tax wealth for themselves and their families.To a better retirement, Bob Carlson Editor, Retirement Watch WeeklyEditor’s Note:American retirees are under attack. Social Security and Medicare are on thin ice. Many retirees are on their own for medical care.  Retirement lasts longer than many expect. And taxes in retirement go up, not down.  No wonder 52% of Americans are financially unprepared for retirement! Yet there are brand-new strategies and “rules” that help you fight back. The only problem is, few people know about them.  Discover the 6 threats to your Retirement in 2026 — and how to overcome them.SPONSOREDThe 3-Day Advantage: Why Winning Traders Think Like Chess MastersIn chess, grandmasters don’t react to the last move. They see 3 moves ahead while their opponent is still processing what just happened.  The same principle separates winning traders from everyone else in February 2026.  While most traders scramble to interpret yesterday’s price action, VantagePoint’s A.I. is already forecasting the next 3 days with up to 87.4% proven accuracy.  Right now, volatility is creating 5 explosive setups. You’re looking at the same charts. But are you seeing 3 moves ahead?  Discover the 3-Day A.I. Advantage – Register Free.CLICK HERE… Want More Retirement Advice? Check out my website, RetirementWatch.com, where you’ll find hundreds of free articles covering every aspect of retirement planning. Popular Posts: Nine Important Things to Know Before Contributing to an IRA How to Help Children or Grandchildren Buy a Home Building the Complete Estate Plan Finding Higher Returns With Low Risk New to the Retirement Watch Community: SeniorResource.com It’s a mistake that’s all too common, and it comes with a lifelong penalty. I’m talking about the DREADED Medicare Part D Penalty. In this week’s SeniorResource, we’ll explain Medicare Part D and the Medicare enrollment periods that run throughout the year. Be careful not to become a victim of Medicare’s LEP. Click here now to learn more.About Bob Carlson: Robert C. Carlson is the author of the books The New Rules of Retirement and Retirement Tax Guide, editor and investment director of the popular retirement newsletter, Retirement Watch, and editor of the free weekly e-letter, Retirement Watch Weekly.  Bob is a frequent speaker at investment conferences around the country, and you can also hear Bob as a featured guest on nationally-syndicated radio shows, such as The Retirement Hour, Dateline Washington, Family News in Focus, The Michael Reagan Show, Money Matters and The Stock Doctor.About Us: Eagle Financial Publications is located in Rosslyn, VA. – Blocks from the Capitol. Our products have been helping investors build their wealth for several decades. Whether you’re a long-term investor or short-term trader, you’ll find the right strategy for you, including how to earn more steady income to spend now, preserve and grow your capital to enjoy later, and whatever other investment goals you have.Visit Our Websites:StockInvestor.comDividendInvestor.comDayTradeSPY.comCoveredCall.comJimFinkInvesting.comGilderReport.comBryanPerryInvesting.comJimWoodsInvesting.comRetirementWatch.comSeniorResource.comGenerationalWealthStrategies.com Visit our YouTube Channel – Eagle Investing Network To ensure future delivery of Eagle Financial Publicationemails please add financial@info2.eaglefinancialpublications.com to your address book or contact list.This email was sent to peterhovis@icloud.com because you are subscribed to Dividend Investor Daily. To unsubscribe from this list please click here. To stop receiving emails simply click here. If you have questions, please send them to Customer Service. View this email in your web browser.Legal Disclaimer: Any and all communications from Eagle Products, LLC. employees should not be considered advice on finances. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized advice on finances.Salem Media Group – Eagle Financial Publications | 1735 N Lynn St, Suite 500, Arlington, VA 22209-2016

Everyone’s watching Nvidia right now. Here’s why I’m excited.

Hey — Tim Sykes here.

So, unless you’ve been living under a rock, you probably saw the news…

Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯

We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.

This isn’t hype—this is real money chasing real AI infrastructure.

And get this… Nvidia earnings are coming up fast.
I’ve seen this setup before. And I’m telling you—it’s giving me flashbacks to the early days of the AI boom.

That’s why I dropped everything to shoot this new VSL for you.

Because I think Nvidia CEO Jensen Huang is getting ready to ignite what I’m calling the AI 2.0 catalyst.

It could be huge.

And no—this isn’t about blindly buying Nvidia.

This is about using my new AI forecasting tool—XGPT—to spot the exact tickers that could pop during this next wave.

We’re talking high-confidence, one-day profit windows. The kind that don’t wait around.

🎯 Click here to watch the video and get the free ticker XGPT just flagged.

I’ll walk you through the story, what I believe is coming next, and how to use AI to trade AI.

Look, I’ve helped mentor over 40 millionaire traders. I’ve made $7.9M trading.

And even I wish I had this tool sooner.

But now it’s your turn.

See you inside,

Tim

---

Sunday’s Bonus Article

Is Abbott’s January Pullback a Good Time to Buy? 

Authored by Thomas Hughes. Published: 1/24/2026. 

At a Glance

• Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
• Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
• A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.

Abbott Laboratories’ (NYSE: ABT) January 2026 pullback has made its stock look attractively valued. The move — driven more by market angst than by any company-specific weakness — appears to be a knee-jerk overreaction that has pushed the stock back into a buy zone.

The gold income breakthrough most investors are missing (Ad)

Gold is soaring, but while the media hypes price predictions, there’s one gold income opportunity no one’s talking about. It’s not a mining stock, not an option trade, and not physical gold you have to store. A quiet fund trading for just $15 has been delivering up to $1,152 a month to regular investors. It’s a smarter, faster way to ride gold’s surge and get paid monthly while you do it.Discover the gold income breakthrough most investors are missing.

That zone corresponds to price action from 2022–2024, when Abbott was recovering from a post-COVID revenue contraction and institutions were actively accumulating the stock.

Abbott Laboratories Growth Accelerates

Although a few metrics missed expectations in Abbott Laboratories’ Q4 results and guidance, revenue of $11.46 billion rose 4.5% year-over-year, margins improved, and adjusted earnings accelerated.

Revenue growth lagged consensus by several hundred basis points, but stronger margins helped offset that: adjusted earnings per share (EPS) increased 12%, slightly above estimates.

By segment, the results highlighted the strength of Abbott’s diversified healthcare portfolio.

Nutrition and Diagnostics contracted—Nutrition fell nearly 9%—but solid growth in Established Pharmaceuticals and Med Tech more than offset those declines.

Established Pharmaceuticals grew about 9%, driven by generics and emerging markets; Med Tech rose roughly 12.3%, with strength across its subsegments.

Margins improved, though they slightly missed some analyst forecasts.

Product-mix shifts, Med Tech strength, reduced COVID-19 sales, and operational improvements collectively boosted margins. Management expects these trends to continue, forecasting earnings growth around 10% in 2026—outpacing revenue—and supporting its capital-return plans.

Abbott’s capital returns are central to the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and it appears positioned to continue that trend. After the pullback the stock yields about 2.5%, and the company pays out less than half of consensus earnings, leaving ample cash flow for share buybacks, which help offset dilution from share-based compensation.

Analysts Point to Robust Rebound in Abbott Laboratories Stock

Some analysts noted the revenue miss, but no major rating or price-target changes were announced the morning of the release. The prevailing view remains that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth.

MarketBeat’s consensus price target implies as much as roughly 30% upside, potentially pushing the stock to new all-time highs; even the low-end target suggests modest upside.

Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion, and acquisitions.

For example, the proposed acquisition of Exact Sciences would broaden Abbott’s revenue and profit streams and expand its product pipeline.

The recent decline has been sharp and could deepen, but institutions accumulated shares throughout 2025 and are likely buyers at these discounted levels.

Early technical support appears around $105–$110, though it is not yet confirmed. Shares could dip to the low end of the target buy zone—possibly to about $95 or lower—before rebounding.

This email is a paid advertisement sent on behalf of Timothy Sykes, a third-party advertiser of MarketBeat. Why was I sent this email?. 


Results are not typical and will vary from person to person. Making money trading stocks takes time, timing, proper execution, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.


If you need help with your subscription, feel free to contact our U.S. based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2026 MarketBeat Media, LLC. 
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. USA..

From Our Partners: Two AI Stocks Getting Quiet Attention (Click to Opt-In)

Everyone’s watching Nvidia right now. Here’s why I’m excited.

Hey — Tim Sykes here.

So, unless you’ve been living under a rock, you probably saw the news…

Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯

We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.

This isn’t hype—this is real money chasing real AI infrastructure.

And get this… Nvidia earnings are coming up fast.
I’ve seen this setup before. And I’m telling you—it’s giving me flashbacks to the early days of the AI boom.

That’s why I dropped everything to shoot this new VSL for you.

Because I think Nvidia CEO Jensen Huang is getting ready to ignite what I’m calling the AI 2.0 catalyst.

It could be huge.

And no—this isn’t about blindly buying Nvidia.

This is about using my new AI forecasting tool—XGPT—to spot the exact tickers that could pop during this next wave.

We’re talking high-confidence, one-day profit windows. The kind that don’t wait around.

🎯 Click here to watch the video and get the free ticker XGPT just flagged.

I’ll walk you through the story, what I believe is coming next, and how to use AI to trade AI.

Look, I’ve helped mentor over 40 millionaire traders. I’ve made $7.9M trading.

And even I wish I had this tool sooner.

But now it’s your turn.

See you inside,

Tim

---

Sunday’s Bonus Article

Is Abbott’s January Pullback a Good Time to Buy? 

Authored by Thomas Hughes. Published: 1/24/2026. 

At a Glance

• Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
• Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
• A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.

Abbott Laboratories’ (NYSE: ABT) January 2026 pullback has made its stock look attractively valued. The move — driven more by market angst than by any company-specific weakness — appears to be a knee-jerk overreaction that has pushed the stock back into a buy zone.

The gold income breakthrough most investors are missing (Ad)

Gold is soaring, but while the media hypes price predictions, there’s one gold income opportunity no one’s talking about. It’s not a mining stock, not an option trade, and not physical gold you have to store. A quiet fund trading for just $15 has been delivering up to $1,152 a month to regular investors. It’s a smarter, faster way to ride gold’s surge and get paid monthly while you do it.Discover the gold income breakthrough most investors are missing.

That zone corresponds to price action from 2022–2024, when Abbott was recovering from a post-COVID revenue contraction and institutions were actively accumulating the stock.

Abbott Laboratories Growth Accelerates

Although a few metrics missed expectations in Abbott Laboratories’ Q4 results and guidance, revenue of $11.46 billion rose 4.5% year-over-year, margins improved, and adjusted earnings accelerated.

Revenue growth lagged consensus by several hundred basis points, but stronger margins helped offset that: adjusted earnings per share (EPS) increased 12%, slightly above estimates.

By segment, the results highlighted the strength of Abbott’s diversified healthcare portfolio.

Nutrition and Diagnostics contracted—Nutrition fell nearly 9%—but solid growth in Established Pharmaceuticals and Med Tech more than offset those declines.

Established Pharmaceuticals grew about 9%, driven by generics and emerging markets; Med Tech rose roughly 12.3%, with strength across its subsegments.

Margins improved, though they slightly missed some analyst forecasts.

Product-mix shifts, Med Tech strength, reduced COVID-19 sales, and operational improvements collectively boosted margins. Management expects these trends to continue, forecasting earnings growth around 10% in 2026—outpacing revenue—and supporting its capital-return plans.

Abbott’s capital returns are central to the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and it appears positioned to continue that trend. After the pullback the stock yields about 2.5%, and the company pays out less than half of consensus earnings, leaving ample cash flow for share buybacks, which help offset dilution from share-based compensation.

Analysts Point to Robust Rebound in Abbott Laboratories Stock

Some analysts noted the revenue miss, but no major rating or price-target changes were announced the morning of the release. The prevailing view remains that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth.

MarketBeat’s consensus price target implies as much as roughly 30% upside, potentially pushing the stock to new all-time highs; even the low-end target suggests modest upside.

Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion, and acquisitions.

For example, the proposed acquisition of Exact Sciences would broaden Abbott’s revenue and profit streams and expand its product pipeline.

The recent decline has been sharp and could deepen, but institutions accumulated shares throughout 2025 and are likely buyers at these discounted levels.

Early technical support appears around $105–$110, though it is not yet confirmed. Shares could dip to the low end of the target buy zone—possibly to about $95 or lower—before rebounding.

This email is a paid advertisement sent on behalf of Timothy Sykes, a third-party advertiser of MarketBeat. Why was I sent this email?. 


Results are not typical and will vary from person to person. Making money trading stocks takes time, timing, proper execution, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk.


If you need help with your subscription, feel free to contact our U.S. based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2026 MarketBeat Media, LLC. 
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. USA..

From Our Partners: Two AI Stocks Getting Quiet Attention (Click to Opt-In)

What juice press failed when bags were squeezed by…

You previously signed up to participate in our trivia, but if you wish to stop participating simply unsubscribe TODAY”S TRIVIAQUESTION 1/10“What juice press failed when bags were squeezed by hand?”SodastreamJuiceroKeurigNespressoPLAY NOW   >>  MORE TRIVIA CATEGORIES:          DISCLAIMERContent labeled as “SPONSORED” may be a third-party advertisement and is not endorsed or warranted by any individual or company as a whole.Want to collaborate? Learn more about our sponsorship opportunities by connecting with us here.© 2024 Trivia Nut. All Rights Reserved.19266 Coastal Hwy Unit 4-536  Rehoboth Beach, DE 19971 Unsubscribe

Seniors Are Raving About This Free Brain Sound That…

Worried your memory’s slipping?  It’s terrifying—not remembering names, appointments, or why you walked into a room. But Harvard found one quick fix: a weird “Brain Sound” that reignites memory in minutes. No pills, no games—just listen. Seniors swear:  No more embarrassing brain blipsMornings with laser-sharp focusRemembering details like you used toTerrified of memory loss?  This changes everything… Click here to hear the Brain Sound for free. Act now—don’t watch your mind slip away.  Listen & remember againBe Fit Digest sending this newsletter on behalf of ACM, LLC  Plеase note: This newsletter, including promotions and updates, was sent to you because you signed up using peter.hovis@gmail.com. If you’d rather not receive these emails anymore, just cliсk to unsubscribе, we respect your choice. UNSUBSCRIBЕ View in Browser If you need assistance, our Support Center is hеre to help with the following: Content-related questions Subscription inquiries and preferences Questions about our services and features Any other important matter you’d like to share with us We’re committed to providing you with thе bеst support, so don’t hesitate to reach out!  Stay connected! By staying subscribed, you’ll receive special offеrs, updates, and helpful information to make the most of our services.  25 SE 2nd Ave Ste 550 PMB Miami, FL 33131 Privacy Policy Terms & Conditions Unsubscribe © 2026 BeFitDigest. All Rights Reserved.

[Confirm email] 5 days to master options in this…

With one, simple strategy, I’m able to day trade options every single morning starting at 9:30am est. 

This one options move allows me to get in and out fast for double-digit gains in about an hour. 

Over the past few years, my alerts would’ve turned 25k into over 1.8 million. 

And I want you to see how to do it with me, live, on camera. 

My name is Mike Shorr. I started my career on the floor of the CBOE in Chicago trading options. My trading firm had months totaling millions in profits. 

Today, I continue to day trade options, but also trade alongside other traders like yourself in my Short Term Options room. 

For 5 days, starting on the 9th… you can join me in my trading room. No cost. No credit card. 

Confirm your email here
Day Trading Options with Mike Shorr in his Trading Room
February 9th – 13th

I’ve never once opened up my trading room to the public for 5 days, for free. Never in 5+ years doing this live. 

You get the first shot in. 

But this may be the only email you get to register. 

If you wish to learn more about day trading options, grab your spot here for next week’s first ever Open House in my day trading options room.

Mike Shorr

Prosper Trading

Founder of the Short Term Options Virtual Trading Floor®

---

Sunday’s Bonus Story

D-Wave’s Big Deal, Bigger Question: Can Sales Catch Up to the Hype?

Reported by Nathan Reiff. Posted: 2/2/2026. 

Key Takeaways

• D-Wave announced two major contracts worth a combined $30 million in late January, shortly after revealing shelf registrations totaling $330 million.
• The company’s revenue doubled year over year in the last reported quarter, but it remains very low in absolute terms.
• One of the contracts, in particular, is for quantum-computing-as-a-service tools and could lead to recurring revenue beyond the initial two-year agreement, a positive sign for D-Wave.

It has been a big year so far for D-Wave Quantum Inc. (NYSE: QBTS). In January the company closed its $550 million cash-and-stock acquisition of Quantum Circuits, significantly expanding D-Wave’s gate-model quantum capabilities. While the deal has reinforced D-Wave’s position as a leading quantum computing player with notable advantages over competitors, shelf registrations totaling $330 million in the first month of the year may also raise concerns about further dilution.

Investors have been cautious: QBTS shares are down about 27% year to date. The Quantum Circuits acquisition boosts D-Wave’s technical credentials, but it doesn’t immediately answer a key investor question — can D-Wave grow sales fast enough to narrow losses and move toward profitability?

2 Sales Landmarks to Start the Year

Central banks are lying to you about gold (Ad)

Jerome Powell says gold is not money. The Fed says inflation is under control and the dollar is strong. But look at what they do. Central banks bought more gold last year than any time since 1967. China dumped $100 billion in U.S. debt, then bought gold. Poland, Hungary, Singapore, and Turkey are all loading up. In 2022, the U.S. froze Russia’s money and showed the world that assets can be seized. Now major nations want out. There’s only one asset no one can freeze: gold.Get the name and ticker of one stock positioned for this shift.

In late January, D-Wave sought to reassure investors about its revenue potential by announcing two notable contracts. Florida Atlantic University agreed to buy and install an Advantage2 annealing system for $20 million, and an unnamed Fortune 100 companysigned a two-year quantum-computing-as-a-service (QCaaS) contract worth $10 million.

These deals represent a meaningful pickup in sales and are a positive early indicator for the year. D-Wave’s revenue growth has been steady but remains modest in absolute terms—revenue more than doubled year over year in the third quarter of 2025, but only reached $3.7 million. The question is whether this momentum will convince investors that D-Wave can sustain the level of sales growth needed after its roughly 255% rally over the past year.

Concerns About Top- and Bottom-Line Performance Linger

Some investors are less focused on the number of contracts and more concerned about their character. One-off system sales of the Advantage2 can produce sizable revenue bumps, but they are finite and do not create recurring revenue. The QCaaS agreement, though light on details so far, could be more valuable if it leads to expanded usage, follow-on purchases, or additional service contracts.

Even with stronger sales, it’s unclear these alone will push D-Wave to profitability. The company appears to have ambitious expansion plans that will continue to draw on cash and likely require additional capital raises—keeping expenses elevated for the foreseeable future. Many recent Advantage2 customers have been universities and municipal organizations, and D-Wave has yet to demonstrate broad adoption across large numbers of corporate clients.

Considerations for Investors

Given these factors, D-Wave may remain too speculative for some investors. The timeline for quantum computing to play a major, everyday role for most businesses and consumers is still uncertain and may be years away.

That said, D-Wave’s dual focus on both gate-model and annealing technologies could prove transformational as the industry matures, and the company has continued to gain commercial traction supported by notable technological progress over the past year.

Valuation is another important consideration. Even after the recent pullback, D-Wave shares have more than tripled over the last year, leaving the company with an extremely high price-to-sales (P/S) ratio of 888.4. Investors should decide whether the latest dip offers an attractive entry point, or whether the stock’s rapid rise has outpaced fundamentals.

Analysts appear optimistic. Thirteen of 15 analysts have rated D-Wave a Buy, and the consensus price target across Wall Street is $38.21—about 88% above the stock price as of early February 2026. Investors may view this analyst support, together with D-Wave’s recent sales agreements, as reason to believe the share price still has room to run.

Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AM newsletter that covers stories that will impact the stock market each day.

This email content is a sponsored message from Prosper Trading Academy, a third-party advertiser of The Early Bird and MarketBeat. 

If you need help with your account, please contact our South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from The Early Bird, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC. 
345 N Reid Pl., Suite 620, Sioux Falls, SD 57103-7078. USA..

From Our Partners: Two AI Stocks Getting Quiet Attention (Click to Opt-In)